Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of-seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU)

International Journal of Clinical Practice

Volumn 58, Issue 2, 2004, Pages 109-118

  Day, James H ^a,b   Briscoe, M P ^a,b   Rafeiro, E ^a   Ratz, J D ^a  

^a KINGSTON GENERAL HOSPITAL   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Allergic rhinitis; Antihistamine; Clinical trial; Comparison; Desloratadine; EEU; Efficacy; Hay fever; Levocetirizine; Nasal congestion

Indexed keywords

ANTIALLERGIC AGENT; CETIRIZINE; DESLORATADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LEVOCETIRIZINE; LORATADINE; PLACEBO;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENVIRONMENTAL EXPOSURE; EYE DISEASE; EYE IRRITATION; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROLOGIC DISEASE; NOSE CONGESTION; NOSE OBSTRUCTION; PAIN; PARALLEL DESIGN; PATIENT SELECTION; PRIORITY JOURNAL; PROVOCATION TEST; RAGWEED POLLEN; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SEASONAL VARIATION; SELF EVALUATION; SINGLE DRUG DOSE; SOMNOLENCE; SYMPTOMATOLOGY; TENSION HEADACHE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; CETIRIZINE; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; MALE; PIPERAZINES; RHINITIS, ALLERGIC, SEASONAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 1842591089     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2004.0117.x     Document Type: Article

References (54)

1. Butland BK, Strachan DP, Lewis S et al. Investigation into the increase in hay fever and eczema at age 16 observed between the 1958 and 1970 British birth cohorts. BMJ 1997; 315: 717-21.
2. Bauchau V, Durham SR, Strachan DP. Epidemiology of allergic rhinitis: Clinical aspects in a population-based sample of adults from six European countries. Eur Respir J 2002; 20: 119S (Abstract).
3. Strachan D, Sibbald B, Weiland S et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol 1997; 8: 161-76.
4. Wright AL, Holberg CJ, Martinez FD et al. Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics 1994; 94: 895-901.
5. American Academy of Allergy Asthma and Immunology. The Allergy Report, volume 1: Overview of Allergic Diseases. Milwaukee, WI, 2000.
6. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991; 21: 77-83.
7. Kremer B, Klimek L, Bullinger M et al. Generic or disease-specific quality of life scales to characterize health status in allergic rhinitis? Allergy 2001; 56: 957-63.
8. Bousquet J, Bullinger M, Fayol C et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 1994; 94: 182-8.
9. Marshall PS, O'Hara C, Steinberg P. Effects of seasonal allergic rhinitis on selected cognitive abilities. Ann Allergy Asthma Immunol 2000; 84: 403-10.
10. Blaiss MS. Cognitive, social, and economic costs of allergic rhinitis. Allergy Asthma Proc 2000; 21: 7-13.
11. Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol 2000; 105: S622-7.
12. Leynaert B, Neukirch F, Demoly P et al. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol 2000; 106: S201-5.
13. Leynaert B, Bousquet J, Neukirch C et al. Perennial rhinitis: An independent risk factor for asthma in nonatopic subjects: Results from the European Community Respiratory Health Survey. J Allergy Clin Immunol 1999; 104: 301-4.
14. Lundback B. Epidemiology of rhinitis and asthma. Clin Exp Allergy 1998; 28 (Suppl. 2): 3-10.
15. Simons FE. A new classification of H1-receptor antagonists. Allergy 1995; 50: 7-11.
16. Potter PC. Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites. Allergy 2003; 58: 893-9.
17. Simons FE, Prenner BM, Finn Jr A. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 2003; 111: 617-22.
18. Leynadier F, Mees K, Arendt C et al. Efficacy and safety of levocetirizine in seasonal allergic rhinitis. Acta Otorhinolaryngol Belg 2001; 55: 305-12.
19. Horak F, Stubner UP, Zieglmayer R et al. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002; 109: 956-61.
20. Grant JA, Riethuisen JM, Moulaert B et al. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: Suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol 2002; 88: 190-7.
21. Denham KJ, Boutsiouki P, Clough GF, Church MK. Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. Inflamm Res 2003; 52: 424-427.
22. Frossard N, Purohit A, Melac M, Pauli G. Comparative activity of levocetirizine and desloratadine 5 mg on histamine-induced skin wheal and flare responses during 24 h. Allergy 2002; 57 (Suppl. 73): 308 (Abstract).
23. Scadding GK. Clinical assessment of antihistamines in rhinitis. Clin Exp Allergy 1999; 29 (Suppl. 3): 77-81.
24. Wilson AM, Orr LC, Coutie WJ et al. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clin Exp Allergy 2002; 32: 126-32.
25. Wang DY, Hanotte F, De Vos C et al. Effect of cetirizine, levocetirizine, and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers. Allergy 2001; 56: 339-43.
26. Berger WE, Schenkel EJ, Mansfield LE. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 2002; 89: 485-91.
27. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001; 56: 1077-80.
28. Guidance for industry (Draft). Allergic Rhinitis: Clinical Development Programs for Drug Products. April 2000. U.S. Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER).
29. Day JH, Briscoe MP. Environmental exposure unit: A system to test anti-allergic treatment. Ann Allergy Asthma Immunol 1999; 83: 83-9.
30. Connell JT. A novel method to assess antihistamine and decongestant efficacy. Ann Allergy 1979; 42: 278-85.
31. Day JH, Buckeridge DL, Clark RH et al. A randomized, double-blind, placebo-controlled, controlled antigen delivery study of the onset of action of aerosolized triamcinolone acetonide nasal spray in subjects with ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1996; 97: 1050-7.
32. Day JH, Briscoe MP, Clark RH et al. Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79: 163-72.
33. Donovan JP, Buckeridge DL, Briscoe MP et al. Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure. Ann Allergy Asthma Immunol 1996; 77: 74-80.
34. Donnelly A, Casale TB. Nedocromil sodium is rapidly effective in the therapy of seasonal allergic rhinitis. J Allergy Clin Immunol 1993; 91: 997-1004.
35. Day JH, Briscoe M, Widlitz MD. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: Effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol 1998; 101: 638-45.
36. Day JH, Briscoe M, Rafeiro E et al. Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: Confirmation of a test system. Ann Allergy Asthma Immunol 2001; 87: 474-81.
37. Solomon WR. Volumetric studies of aeroallergen prevalence. I. Pollens of weedy forbs at a midwestern station. J Allergy Clin Immunol 1976; 57: 318-27.
38. Habenicht HA, Burge HA, Muilenberg ML et al. Allergen carriage by atmospheric aerosol. II. Ragweed-pollen determinants in submicronic atmospheric fractions. J Allergy Clin Immunol 1984; 74: 64-7.
39. Clough GF, Boutsiouki P, Church MK. Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin. Allergy 2001; 56: 985-8.
40. Henz BM. The pharmacologic profile of desloratadine: A review. Allergy 2001; 56 (Suppl. 65): 7-13.
41. Tillement JP. A low distribution volume as a determinant of efficacy and safety for histamine (H1) antagonists. Allergy 1995; 50: 12-6.
42. Tillement JP. The advantages for an H1 antihistamine of a low volume of distribution. Allergy 2000; 55 (Suppl. 60): 17-21.
43. Young T, Finn L, Kim H. Nasal obstruction as a risk factor for steep-disordered breathing. The University of Wisconsin Sleep and Respiratory Research Group. J Allergy Clin Immunol 1997; 99: S757-62.
44. Cotten J. Allergic rhinitis and asthma: How important is the link? J Allergy Clin Immunol 1997; 99: S781-6.
45. Howarth PH, Salagean M, Dokic D. Allergic rhinitis: Not purely a histamine-related disease. Allergy 2000; 55 (Suppl. 64): 7-16.
46. Assanasen P, Naclerio RM. Antiallergic anti-inflammatory effects of H1-antihistamines in humans. Clin Allergy Immunol 2002; 17: 101-39.
47. Michel L, Jean-Louis F, Dubertret L. Pharmacological study of levocetirizine in Ig-E dependent hypersensitivity cutaneous reaction in grass pollen allergic volunteers. Demonstration of mediator release and eosinophil recruitment modulation by levocetirizine. Allergy 2001; 56 (Abstract).
48. Thomson L, Blaylock MG, Sexton DW et al Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells. Clin Exp Allergy 2002; 32: 1187-92.
49. Salmun LM, Lorber R. 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]. BMC Fam Pract 2002; 3: 14.
50. Day JH, Briscoe MP, Rafeiro E et al. Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: Duration of effect in subjects with seasonal allergic rhinitis. Allergy Asthma Proc 2004; 25: 59-68.
51. Hindmarch I, Johnson S, Meadows R et al. The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare. Curr Med Res Opin 2001; 17: 241-55.
52. Gandon JM, Allain H. Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers. Br J Clin Pharmacol 2002; 54: 51-8.
53. Verster JC, Volkerts ER, Van Oosterwijck AW et al. Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood. J Allergy Clin Immunol 2003; 111: 623-7.
54. Verster JC, De Weert AM, Bijtjes SI et al. Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: A randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2003; 169: 84-90.